48,830
edits
m (→IHC: more) |
|||
Line 37: | Line 37: | ||
**Desmoidtype [[fibromatosis]] (~70%), solitary fibrous tumour & endometrial stromal sarcoma (~40%), synovial sarcoma (~30%).<ref name=pmid15375433>{{cite journal |author=Ng TL, Gown AM, Barry TS, ''et al.'' |title=Nuclear beta-catenin in mesenchymal tumors |journal=Mod. Pathol. |volume=18 |issue=1 |pages=68–74 |year=2005 |month=January |pmid=15375433 |doi=10.1038/modpathol.3800272 |url=}}</ref> | **Desmoidtype [[fibromatosis]] (~70%), solitary fibrous tumour & endometrial stromal sarcoma (~40%), synovial sarcoma (~30%).<ref name=pmid15375433>{{cite journal |author=Ng TL, Gown AM, Barry TS, ''et al.'' |title=Nuclear beta-catenin in mesenchymal tumors |journal=Mod. Pathol. |volume=18 |issue=1 |pages=68–74 |year=2005 |month=January |pmid=15375433 |doi=10.1038/modpathol.3800272 |url=}}</ref> | ||
==== | ====DJH panels==== | ||
=====MFH===== | |||
*Vimentin. | *Vimentin. | ||
*Keratin 5D3 - carcinomas. | |||
*Keratin LP34 - carcinomas. | |||
*Keratin 5D3. | |||
*Keratin LP34. | |||
*EMA. | *EMA. | ||
*CD99. | |||
*MSA. | *MSA. | ||
*SMA. | |||
*Caldesmon. | *Caldesmon. | ||
* | *CD34. | ||
*HMB45 | *S-100 - neural tumours. | ||
*Mart-1. | *HMB45 - [[melanoma]] | ||
*Mart-1 - [[melanoma]]. | |||
*Tyrosinase. | *Tyrosinase. | ||
*MYF-4 - [[RMS]]. | |||
*Alpha-1-antichymotrypsin. | |||
=====SRCT===== | |||
Same as MFH panel plus the following: | |||
*CD45. | |||
*CD30. | |||
*CD3. | |||
*CD20. | |||
*Desmin. | |||
*CD31 - [[angiosarcoma]]. | |||
*Factor VIII - [[angiosarcoma]]. | |||
==See also== | ==See also== |
edits